首页> 外文期刊>Orthopaedic Journal of Sports Medicine >Comparing Intra-articular Injections of Leukocyte-Poor Platelet-Rich Plasma Versus Low–Molecular Weight Hyaluronic Acid for the Treatment of Symptomatic Osteoarthritis of the Hip: A Double-Blind, Randomized Pilot Study
【24h】

Comparing Intra-articular Injections of Leukocyte-Poor Platelet-Rich Plasma Versus Low–Molecular Weight Hyaluronic Acid for the Treatment of Symptomatic Osteoarthritis of the Hip: A Double-Blind, Randomized Pilot Study

机译:比较白细胞贫乏血小板血小板血浆的关节内注射与低分子量透明质酸的治疗髋关节骨质性骨关节炎:双盲,随机试验研究

获取原文
           

摘要

Background: Hyaluronic acid (HA) and leukocyte-poor platelet-rich plasma (LP-PRP) are 2 nonoperative treatment options that have been studied in patients with hip osteoarthritis (OA). Purpose: To compare the efficacy of intra-articular injections of low–molecular weight (LMW) HA and LP-PRP in patients with hip OA. Study Design: Randomized controlled trial; Level of evidence, 1. Methods: A total of 34 patients (36 hips) presenting with signs of hip OA were randomized to receive 3 blinded, weekly intra-articular injections of either LP-PRP or LMW-HA. Patients were prospectively evaluated before injections and at 6 weeks and then at 3, 6, 12, and 24 months. The primary outcome, conversion to total hip arthroplasty (THA) or a hip resurfacing procedure, was analyzed along with secondary outcomes including the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score and hip range of motion. Results: The final analysis included 33 hips (mean Kellgren-Lawrence grade, 2.73) (LMW-HA: n = 14; LP-PRP: n = 19) in 31 patients (18 male; mean age, 53.8 years). Significantly more patients converted to THA or a hip resurfacing procedure in the LMW-HA group (7/14; 50.0%) (mean, 1.3 years after first injection) than the LP-PRP group (3/19; 15.8%) (mean, 0.73 years after first injection) ( P = .035). There was no significant improvement or decline in any outcome scores within the LMW-HA group from before injections to 6 weeks or 3, 6, and 12 months. For the LP-PRP group, WOMAC overall ( P = .032), joint ( P = .030), and function scores ( P = .025) significantly improved from before injections to 6 weeks, and WOMAC joint scores significantly improved from before injections to 6 months ( P = .036). When comparing the difference between groups in internal rotation at 90° of hip flexion from before injections to 6 months, the LP-PRP group demonstrated a mean 5.0° improvement, while the LMW-HA group showed a mean 1.5° decrease ( P = .028). Conclusion: Intra-articular hip injections of LP-PRP in patients with hip OA resulted in an improvement in WOMAC scores and hip internal rotation at 6 months and delayed the need for THA or a hip resurfacing procedure compared with treatment with LMW-HA. A longer follow-up is necessary to further compare the effects of LP-PRP and LMW-HA injections in patients with hip OA. Registration: NCT01920152 ( ClinicalTrials.gov identifier).
机译:背景技术透明质酸(HA)和白细胞贫乏血小板血浆(LP-PRP)是髋关节骨关节炎(OA)患者研究的2种非手术治疗方案。目的:比较髋臼患者的关节内注射患者的关节内注射和LP-PRP的疗效。研究设计:随机对照试验;证据水平,1.方法:34名患者(36名髋关节)呈现出髋部OA迹象的患者被随机分配接受3例盲目的,每周内关节内注射LP-PRP或LMW-HA。患者在注射前并在6周内进行预期评估,然后在3,6,12和24个月内进行评估。分析了对总髋关节置换术(THA)或髋关节性关节成形术(THA)或髋关节重构程序的主要结果以及包括西部安大略省和麦克马斯特大学骨关节炎指数(WOWAC)评分和髋关节运动范围的二次结果。结果:终原分析包括33髋(平均Kellgren-Lawrence级,2.73)(LMW-HA:N = 14; LP-PRP:n = 19),在31名患者中(18名男性;平均年龄,53.8岁)。在LMW-HA组(7/14; 50.0%)(第一次注射后7/14; 50.0%)(平均值,1.3岁)中转化为THA或髋关节重新铺设程序的患者比LP-PRP组(3/19; 15.8%)(平均值)(平均值,第一次注射后0.73岁)(p = .035)。 LMW-HA组在注射前的任何结果评分中没有显着改善或下降至6周或3,6和12个月。对于LP-PRP组,WOMAC总体(P = .032),关节(P = .030)和功能评分(P = .025)从注射之前显着改善到6周之前,并且WOMAC联合评分从之前显着改善注射到6个月(p = .036)。当从注射之前在90°屈曲的内部旋转中的基团之间的差异比较6个月时,LP-PRP组展示平均5.0°的改善,而LMW-HA组显示平均1.5°降低(P =。 028)。结论:髋部OA患者的关节内髋关节注射率为LP-PRP导致6个月内的WOMAC分数和髋关节内部旋转,并延迟了与LMW-HA的治疗相比的THA或HIP Resurfacing程序的需要。更长的随访是必要的,以进一步比较LP-PRP和LMW-HA注射患者髋部oA患者的影响。注册:NCT01920152(ClinicalTrials.gov标识符)。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号